[go: up one dir, main page]

WO2014060851A3 - Hepatitis c virus immunogenic compositions and methods of use thereof - Google Patents

Hepatitis c virus immunogenic compositions and methods of use thereof Download PDF

Info

Publication number
WO2014060851A3
WO2014060851A3 PCT/IB2013/003029 IB2013003029W WO2014060851A3 WO 2014060851 A3 WO2014060851 A3 WO 2014060851A3 IB 2013003029 W IB2013003029 W IB 2013003029W WO 2014060851 A3 WO2014060851 A3 WO 2014060851A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunogenic compositions
methods
hepatitis
hcv
virus immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/003029
Other languages
French (fr)
Other versions
WO2014060851A2 (en
Inventor
John Law
Michael Logan
Darren HOCKMAN
D. Lorne Tyrrell
Michael Houghton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Alberta
Original Assignee
University of Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Alberta filed Critical University of Alberta
Publication of WO2014060851A2 publication Critical patent/WO2014060851A2/en
Publication of WO2014060851A3 publication Critical patent/WO2014060851A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present disclosure provides immunogenic compositions comprising HCV El and modified E2 polypeptides, wherein the modified E2 polypeptide comprises an amino acid substitution of asparagine in an E2N1 and/or E2N6 site. The immunogenic compositions are useful in earning out methods of inducing an immune response to HCV. The present disclosure further provides methods of stimulating an immune response to HCV in an individual.
PCT/IB2013/003029 2012-10-05 2013-10-04 Hepatitis c virus immunogenic compositions and methods of use thereof Ceased WO2014060851A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261710533P 2012-10-05 2012-10-05
US61/710,533 2012-10-05
US201261729135P 2012-11-21 2012-11-21
US61/729,135 2012-11-21

Publications (2)

Publication Number Publication Date
WO2014060851A2 WO2014060851A2 (en) 2014-04-24
WO2014060851A3 true WO2014060851A3 (en) 2014-09-12

Family

ID=50488838

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/003029 Ceased WO2014060851A2 (en) 2012-10-05 2013-10-04 Hepatitis c virus immunogenic compositions and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2014060851A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014385320B2 (en) * 2013-05-15 2019-10-10 The Governors Of The University Of Alberta E1E2 HCV vaccines and methods of use
US10300131B2 (en) 2015-07-07 2019-05-28 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
US11186615B2 (en) 2015-10-08 2021-11-30 The Governors Of The University Of Alberta Hepatitis C virus E1/E2 heterodimers and methods of producing same
US12048742B2 (en) 2018-03-16 2024-07-30 The Governors Of The University Of Alberta Hepatitis C virus peptide compositions and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FALKOWSKA, E. ET AL., JOURNAL OF VIROLOGY., vol. 81, no. 15, August 2007 (2007-08-01), pages 8072 - 8079 *
HELLE, F. ET AL.: "Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious vinons.", JOURNAL OF VIROLOGY, vol. 84, no. 22, November 2010 (2010-11-01), pages 11905 - 11915 *
HELLE, F. ET AL.: "The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein.", JOURNAL OF VIROLOGY, vol. 81, no. 15, August 2007 (2007-08-01), pages 8101 - 8111 *

Also Published As

Publication number Publication date
WO2014060851A2 (en) 2014-04-24

Similar Documents

Publication Publication Date Title
WO2017070626A3 (en) Respiratory virus vaccines
MX2012009581A (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease.
NZ630869A (en) Compositions and methods for dengue virus chimeric constructs in vaccines
HK1215595A1 (en) Interleukin-10 compositions and uses thereof
JP2011136997A5 (en)
WO2009026397A3 (en) Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
DK2707393T3 (en) FUSION PROTEINS AND COMBINATION VACCINES COVERING HAEMOPH-ILUS INFLUENZAE PROTEIN E AND PILIN A
EP2897640A4 (en) PROTEIN C UR OF HEPATITIS B VIRUS, ANTIGENIC SURFACE PROTEIN, AND VACCINE COMPRISING THE SAME
WO2010036970A3 (en) Influenza vaccines, antigens, compositions, and methods
CR20140421A (en) PESTICIDE CEPA OF FLAVOBACTERIUM AND BIOACTIVE COMPOSITIONS, METABOLITES AND USES OF THE SAME
TR201905619T4 (en) Peptide carrier fusion proteins as allergy vaccines.
WO2015052543A3 (en) Malaria vaccination
WO2015020913A3 (en) Influenza hemagglutinin proteins and methods of thereof
IN2012DN03209A (en)
PH12015500499A1 (en) Recombinant measles virus expressing chikungunya virus polypeptides and their applications
BR112013030396A2 (en) polypeptide, polynucleotide, vector, host cell, immunogenic composition, vaccine, and use of an immunogenic composition or vaccine
PH12017500450A1 (en) Flavivirus virus like particle
WO2012054907A3 (en) Novel hemagglutinin 5 (h5) proteins for the treatment and prevention of influenza infections
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
IN2015DN03206A (en)
NZ602380A (en) Peptides for vaccine against birch allergy
WO2014060851A3 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
MX363149B (en) Influenza nucleoprotein vaccines.
EA033027B1 (en) Attenuated swine influenza vaccines and methods of making and use thereof

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13846770

Country of ref document: EP

Kind code of ref document: A2